Skip to main content
Premium Trial:

Request an Annual Quote

Atugen Will Use siRNA Tools, GeneBlocs Tech to Help Sankyo Validate Drug Targets

NEW YORK, May 17 (GenomeWeb News) - Atugen will use its siRNA technology and GeneBlocs platform to help Japanese drug maker Sankyo validate certain undisclosed therapeutic targets.

 

Atugen, based in Berlin, will use its tools, which also include delivery reagents and functional assays, to validate an undisclosed number of Sankyo targets.

This is the second collaboration between the two companies.

Financial details of the agreement were not disclosed.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more